

type of report	Current report
number	39/2014
company	Pharmena Spółka Akcyjna

The first patient finished clinical trial concerning 1-MNA anti-atherogenic drug

With reference to Company's Strategy for the years 2012-2015 (published in the current report No. 16/2012 of 13th April 2012), as well as the statement on the advancement of clinical trials concerning the innovative 1-MNA anti-atherogenic drug (published in the current report No. 19/2014 of 1st April 2014) the Board of PHARMENA S.A Company informs that the first patient finished II phase clinical trial of 1-MNA anti-atherogenic drug on 17th July 2014.

The aim of II phase clinical trial concerning 1-MNA anti-atherogenic drug is to establish an effective dose of the drug as well as to confirm the lack of side effects in people, as far as administered drug doses are concerned. Montreal Heart Institute is the entity supervising the clinical trial.

II phase clinical trials ("Proof of Concept") are financed from the funds obtained from series D shares issue.

The Company shall inform about Progress of trials concerning the innovative anti-atherogenic drug 1-MNA in the following current reports.

This information has been stated, since conducting II phase clinical trials is indispensable to commercialise the project of the 1-MNA anti-atherogenic drug, whereas possible income from commercialisation of the drug may pose a considerable influence on financial results and market valuation of the Issuer.

Legal basis: § 3 par. 1 of the Annex No. 3 to Alternative Trading System Rules "Current and Periodical Information in the Alternative Trading System on the NewConnect Market".

Representatives of the company:

- Konrad Palka – President of the Board
- Marzena Wieczorkowska – Vice President of the Board